show episodes
 
Loading …
show series
 
Launch prices in oncology have been rising -- a reflection, in part, of the growing clinical power of the medicines -- raising the question whether doctors, payers and others might try to push down prices of cancer medicines. Loncar Investment's Brad Loncar joins us to lend his perspective on the issue in a conversation that touches on the rise of …
 
The COVID-19 pandemic has served as a wake-up call for the healthcare ecosystem to recognize the urgencies of working together to achieve life-changing, economy-saving advancements. Leslie Isenegger interview Center for Medicine in the Public Interest President Peter Pitts about his new book, The Value Equation: A Journey Through the Innovation Eco…
 
Early legislative language from the House of Representatives on the newest COVID-19 stimulus bill includes a provision to remove the "rebate cap" in Medicaid. That has the potential to put drugmakers in a position where they are paying states every time certain medicines are prescribed. We interview West Health's Sean Dickson to understand how the …
 
Well, it's 2020, so it shouldn't be surprising that the United States awoke the morning after Election Day to uncounted ballots and unanswered questions. Fortunately, W2O Group Director Courtney Tyne joined the podcast to make sense of where things stand -- 12 hours after polls closed -- on drug pricing and access policy. The short version: expect …
 
The Association for Accessible Medicines' new president and CEO, Dan Leonard, goes behind the mic to talk about the pathway to his new gig, the promise of biosimilars, what the 2020 election means for the generic drug industry, and why COVID-19 has underscored the public health impact of generic drugs. Keep up with Dan on Twitter.…
 
Brian talks to Ted Slafsky, the founder and principal of Wexford Solutions and publisher and CEO of 340B Report. 340B -- the program under which certain health care entities that treat underserved populations can get reduced-price prescription drugs -- has become a flashpoint this year, with six pharmaceutical companies announcing plans to restrict…
 
Peter Kolchinsky, RA Capital's founder and managing partner, joins to talk about why so many of the policy ideas floated around drug-pricing are wrongheaded. Industry is going to have to give "a pound of flesh," Kolchinsky argued, and he's explicit on the business practices biopharma must abandon to get a fair system that still rewards innovation. …
 
PRECISIONheor Vice President Jason Shafrin pops in to talk about the Institute of Clinical and Economic Review and the broader question of where the group's influence is centered and the elements of ICER reports that stakeholders are paying attention to. For more from Jason, check of his work at Healthcare-Economist.com.…
 
Loading …

Quick Reference Guide

Copyright 2021 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login